查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1574965

朊病毒疾病治療市場，按類型、治療、最終用戶、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Prion Disease Treatment Market, By Type, By Treatment, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年朊病毒疾病治療市場規模為49.8498億美元，2024年至2032年複合年成長率為4.99%。

朊病毒疾病治療市場-市場動態

人們對針對特定朊病毒株的個人化醫療的興趣日益濃厚，推動了利基市場的成長。

人們對針對特定朊病毒株的個人化醫療日益成長的興趣是市場擴張的關鍵驅動力。這種方法根據不同人群菌株的獨特特徵來客製化診斷和治療，提高介入措施的有效性。美國國家神經疾病和中風研究所 (NINDS) 的最新資料表明，個人化醫療策略可以將朊病毒疾病的診斷準確性提高高達 30%。這些進步凸顯了更精確、更有效的治療方案的潛力，直接影響市場動態。

隨著醫療保健行業擴大採用個人化方法，對專業診斷工具和客製化療法的需求不斷成長。這種需求促進了帕金森氏症管理利基市場的創新和成長，強調了個人化醫療在解決複雜的神經退化性疾病方面的變革潛力。

朊病毒疾病治療市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 4.99% 左右的複合年成長率成長

根據類型細分，庫賈氏病 (CJD) 預計將在 2023 年顯示最大的市場佔有率

根據治療細分，抗憂鬱藥物是 2023 年的主要藥物類型

按地區分類，北美是 2023 年的主要收入來源

朊病毒疾病治療市場-細分分析：

全球朊病毒病治療市場根據類型、治療、最終用戶和地區進行細分。

市場依類型分為四類：庫賈氏病（CJD）、變異型庫賈氏病（CJD）、可變蛋白酶敏感性朊病毒病、格斯特曼-施特勞斯勒-沙因克病、其他。在朊病毒病治療市場中，庫賈氏病（CJD）是最突出且最重要的部分。庫賈氏病是人類最常見的朊病毒疾病，與其他朊病毒疾病相比，它的盛行率較高，因此成為人們關注的焦點。庫賈氏病有多種形式，包括散發性、遺傳性和後天性。散髮型是最常見的，發生時沒有任何已知原因。由於研究興趣高且疾病性質嚴重，庫賈氏病的治療前景特別活躍。開發庫賈氏病有效療法或療法的努力往往會推動市場發展，使其成為主導細分市場。

根據治療方法，市場分為兩類：抗憂鬱藥、抗精神病藥和其他藥物。在朊病毒疾病治療市場中，與抗精神病藥物相比，抗憂鬱藥物更為突出且重要。抗憂鬱藥物通常用於治療朊病毒病，特別是用於緩解憂鬱、焦慮和躁動等症狀，這些症狀在庫賈氏病 (CJD) 等朊病毒病患者中很常見。儘管朊病毒病無法治愈，但抗憂鬱藥物可以透過控制繼發症狀來幫助改善生活品質。朊病毒疾病的研究和治療策略中對抗憂鬱藥物的關注使得這一細分市場更加重要並在市場上佔據主導地位。

朊病毒疾病治療市場-地理洞察

在北美，朊病毒病治療是一個正在進行的研究領域，但臨床選擇有限。朊病毒疾病，例如庫賈氏病 (CJD)，非常罕見，其特徵是進行性神經退化。治療策略著重於症狀管理和實驗療法。人們非常重視開發有效藥物的研究，多項臨床試驗探索新的化合物和方法，例如基因療法和免疫療法。

儘管朊病毒疾病的複雜性帶來了挑戰，但北美監管環境透過資金和監管途徑支持這些努力。研究機構、醫療保健提供者和製藥公司之間的合作對於推進治療方案和改善患者治療效果至關重要。

朊病毒疾病治療市場-競爭格局：

朊病毒疾病治療的競爭格局包括各種生物技術和製藥公司應對這些疾病的獨特挑戰。 CureVac AG 正在探索 mRNA 技術的潛在治療方法，而 Prionics AG 則專注於朊病毒疾病診斷。 Neurotech Pharmaceuticals 和 Prothena Biosciences 正在開發可能與朊病毒疾病相關的神經退化性疾病的療法。 Alnylam Pharmaceuticals 和 IONIS Pharmaceuticals 致力於研究可能影響朊病毒病治療的 RNA 療法。百健（Biogen）、禮來公司（Eli Lilly and Company）和安進公司（Amgen Inc.）等主要參與者投資於更廣泛的神經退化研究，以及潛在的朊病毒疾病治療方法。基因泰克（羅氏集團）專注於創新的神經療法。 Wave Life Sciences 和 Orphazyme A/S 分別正在探索 RNA 標靶療法和罕見疾病療法。 Sage Therapeutics 致力於治療神經退化性疾病，而 Alector Inc. 則開發免疫療法。 Tetra Discovery Partners 也正在研究可能與朊病毒疾病相關的神經系統疾病的治療方法。這個多元化的公司集團凸顯了旨在解決朊病毒疾病的複雜性的持續努力和創新。

最新進展：

2024 年 6 月，CHARMED 合作推出了一種有前景的朊病毒疾病治療候選藥物，可能為這些目前無法治療的致命疾病帶來新的希望。

2023年8月，Elite Pharmaceuticals Inc.宣布EP-1已被FDA授予治療庫賈氏病的快速通道資格。該程序被稱為“快速通道指定”，旨在加速和簡化旨在治療嚴重或危及生命的疾病的藥物的開發。

目錄

第1章：朊病毒疾病治療市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按類型分類的朊病毒疾病治療市場片段
    • 朊病毒疾病治療市場片段（依治療）
    • 最終使用者的朊病毒疾病治療市場片段
    • 按國家/地區分類的朊病毒疾病治療市場片段
    • 按地區分類的朊病毒疾病治療市場片段
  • 競爭洞察

第 3 章：朊病毒病治療主要市場趨勢

  • 朊病毒疾病治療市場促進因素
    • 市場促進因素的影響分析
  • 朊病毒疾病治療市場限制
    • 市場限制影響分析
  • 朊病毒疾病治療市場機會
  • 朊病毒疾病治療市場未來趨勢

第 4 章：朊病毒疾病治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：朊病毒疾病治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：朊病毒疾病治療市場格局

  • 2023 年朊病毒疾病治療市佔率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：朊病毒疾病治療市場 - 按類型

  • 概述
    • 按類型分類的細分市場佔有率分析
    • 庫賈氏病 (CJD)
    • 變異型庫賈氏病 (CJD)
    • 不同蛋白酶敏感性朊病毒病
    • 格斯特曼-施特勞斯勒-沙因克病
    • 其他

第 8 章：朊病毒疾病治療市場 - 按治療分類

  • 概述
    • 按處理方式分類的細分市場佔有率分析
    • 抗憂鬱藥
    • 抗精神病藥
    • 其他

第 9 章：朊病毒疾病治療市場 - 按最終用戶

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院
    • 家庭護理設置
    • 其他

第 10 章：朊病毒疾病治療市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美朊病毒疾病治療主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按類型）
    • 北美市場規模與預測（以不同處理方式）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲朊病毒疾病治療主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模與預測（按類型）
    • 歐洲市場規模與預測（按處理方式）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區朊病毒疾病治療主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（按類型）
    • 亞太地區市場規模與預測（以不同處理方式）
    • 亞太地區市場規模和預測（按最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲朊病毒疾病治療主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按類型）
    • 拉丁美洲市場規模與預測（以不同處理方式）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲朊病毒疾病治療主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按類型）
    • 中東及非洲市場規模及預測（依不同處理方式）
    • 中東和非洲市場規模和預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - 朊病毒疾病治療產業

  • 競爭儀表板
  • 公司簡介
    • CureVac AG
    • Prionics AG
    • Neurotech Pharmaceuticals
    • Prothena Biosciences
    • Alnylam Pharmaceuticals
    • IONIS Pharmaceuticals
    • Biogen
    • Eli Lilly and Company
    • Amgen Inc.
    • Genentech
    • Wave Life Sciences
    • Orphazyme A/S
    • Sage Therapeutics
    • Alector Inc.
    • Tetra Discovery Partners

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4039

REPORT HIGHLIGHT

Prion Disease Treatment Market size was valued at USD 4,984.98 million in 2023, expanding at a CAGR of 4.99% from 2024 to 2032.

Prion diseases are a group of progressive neurodegenerative disorders caused by abnormal, misfolded proteins known as prions. These prions induce other proteins in the brain to also misfold, leading to brain damage and severe neurological symptoms. The most well-known prion diseases include Creutzfeldt-Jakob disease, Bovine Spongiform Encephalopathy (mad cow disease), and Kuru. Symptoms often involve rapid cognitive decline, motor dysfunction, and behavioral changes. Currently, there is no cure for prion diseases, and treatment mainly focuses on alleviating symptoms and providing supportive care. Research is ongoing to find effective therapies, but the unique nature of prions and their ability to resist conventional treatments pose significant challenges. Early diagnosis and management can help in improving the quality of life for affected individuals.

Prion Disease Treatment Market- Market Dynamics

Rising interest in personalized medicine for specific prion strains drives niche market growth.

The growing interest in personalized medicine for specific prion strains is a key driver of market expansion. This approach tailors' diagnostics and treatments to the unique characteristics of different population strains, enhancing the effectiveness of interventions. Recent data from the National Institute of Neurological Disorders and Stroke (NINDS) showed that personalized medicine strategies could improve diagnostic accuracy for prion diseases by up to 30%. These advancements highlight the potential for more precise and effective treatment options, directly influencing market dynamics.

As the healthcare sector increasingly embraces individualized approaches, there is a rising demand for specialized diagnostic tools and customized therapies. This demand fosters innovation and growth in the niche market for Parkinson's disease management, emphasizing the transformative potential of personalized medicine in addressing complex neurodegenerative conditions.

Prion Disease Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.99% over the forecast period (2024-2032)

Based on Type segmentation, Creutzfeldt-Jakob Disease (CJD) was predicted to show maximum market share in the year 2023

Based on Treatment segmentation, antidepressant medications was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Prion Disease Treatment Market- Segmentation Analysis:

The Global Prion Disease Treatment Market is segmented on the basis of Type, Treatment, End User, and Region.

The market is divided into four categories based on Type: Creutzfeldt-Jakob Disease (CJD), Variant Creutzfeldt-Jakob Disease (CJD), Variably Protease-Sensitive Prionopathy, Gerstmann-Straussler-Scheinker Disease, Others. In the prion disease treatment market, Creutzfeldt-Jakob Disease (CJD) is the most prominent and significant segment. CJD is the most common prion disease in humans, and it is a major focus due to its prevalence compared to other prion disorders. Creutzfeldt-Jakob Disease comes in several forms, including sporadic, genetic, and acquired. The sporadic form is the most common and occurs without any known cause. The treatment landscape for CJD is particularly active due to the high level of research interest and the severe nature of the disease. Efforts to develop effective treatments or therapies for CJD often drive the market, making it the dominant segment.

The market is divided into two categories based on Treatment: Antidepressants, Antipsychotic agents, and Others. In the prion disease treatment market, antidepressant medications are more prominent and significant compared to antipsychotic agents. Antidepressants are often used in the management of prion diseases, particularly for alleviating symptoms such as depression, anxiety, and agitation, which are common in patients with prion disorders like Creutzfeldt-Jakob Disease (CJD). Although there is no cure for prion disease, antidepressants can help improve the quality of life by managing secondary symptoms. The focus on antidepressants in research and treatment strategies for prion diseases makes this segment more significant and dominant in the market.

Prion Disease Treatment Market- Geographical Insights

In North America, prion disease treatment is an area of ongoing research with limited clinical options. Prion diseases, such as Creutzfeldt-Jakob Disease (CJD), are rare and characterized by progressive neurodegeneration. Treatment strategies focus on symptomatic management and experimental therapies. There is a significant emphasis on research to develop effective drugs, with several clinical trials exploring novel compounds and approaches, such as gene therapy and immunotherapy.

The North American regulatory environment supports these efforts through funding and regulatory pathways, though the complexity of prion diseases presents challenges. Collaboration among research institutions, healthcare providers, and pharmaceutical companies is crucial for advancing treatment options and improving patient outcomes.

Prion Disease Treatment Market- Competitive Landscape:

The competitive landscape for prion disease treatment includes a variety of biotech and pharmaceutical companies tackling the unique challenges of these disorders. CureVac AG is exploring mRNA technologies for potential treatments, while Prionics AG specializes in prion disease diagnostics. Neurotech Pharmaceuticals and Prothena Biosciences are developing therapies for neurodegenerative conditions that could be relevant to prion diseases. Alnylam Pharmaceuticals and IONIS Pharmaceuticals work on RNA-based therapies that may impact prion disease treatment. Major players such as Biogen, Eli Lilly and Company, and Amgen Inc. invest in broader neurodegenerative research with potential Treatments to prion diseases. Genentech (Roche Group) focuses on innovative neurological therapies. Wave Life Sciences and Orphazyme A/S are exploring RNA-targeted and rare disease therapies, respectively. Sage Therapeutics works on neurodegenerative disorders, while Alector Inc. develops immunotherapies. Tetra Discovery Partners is also researching treatments for neurological conditions that might intersect with prion diseases. This diverse group of companies highlights the ongoing efforts and innovations aimed at addressing the complex nature of prion diseases.

Recent Developments:

In June 2024, The CHARMED collaboration unveiled a promising treatment candidate for prion diseases, potentially offering new hope for these currently untreatable and fatal conditions.

In August 2023, Elite Pharmaceuticals Inc. declared that EP-1 had been given the Fast Track designation by the FDA to treat CJD. The procedure known as "Fast Track designation" intended to speed up and simplify the development of medications aimed at treating serious or life-threatening illnesses.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PRION DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • CureVac AG
  • Prionics AG
  • Neurotech Pharmaceuticals
  • Prothena Biosciences
  • Alnylam Pharmaceuticals
  • IONIS Pharmaceuticals
  • Biogen
  • Eli Lilly and Company
  • Amgen Inc.
  • Genentech
  • Wave Life Sciences
  • Orphazyme A/S
  • Sage Therapeutics
  • Alector Inc.
  • Tetra Discovery Partners

GLOBAL PRION DISEASE TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Creutzfeldt-Jakob Disease (CJD)
  • Variant Creutzfeldt-Jakob Disease (CJD)
  • Variably Protease-Sensitive Prionopathy
  • Gerstmann-Straussler-Scheinker Disease
  • Others

GLOBAL PRION DISEASE TREATMENT MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Antidepressant
  • Antipsychotic Agents
  • Others

GLOBAL PRION DISEASE TREATMENT MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Homecare settings
  • Others

GLOBAL PRION DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Prion Disease Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Prion Disease Treatment Market Snippet by Type
    • 2.1.2. Prion Disease Treatment Market Snippet by Treatment
    • 2.1.3. Prion Disease Treatment Market Snippet by End User
    • 2.1.4. Prion Disease Treatment Market Snippet by Country
    • 2.1.5. Prion Disease Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Prion Disease Treatment Key Market Trends

  • 3.1. Prion Disease Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Prion Disease Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Prion Disease Treatment Market Opportunities
  • 3.4. Prion Disease Treatment Market Future Trends

4. Prion Disease Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Prion Disease Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Prion Disease Treatment Market Landscape

  • 6.1. Prion Disease Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Prion Disease Treatment Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Creutzfeldt-Jakob Disease (CJD)
    • 7.1.3. Variant Creutzfeldt-Jakob Disease (CJD)
    • 7.1.4. Variably Protease-Sensitive Prionopathy
    • 7.1.5. Gerstmann-Straussler-Scheinker Disease
    • 7.1.6. Others

8. Prion Disease Treatment Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2023 & 2032 (%)
    • 8.1.2. Antidepressant
    • 8.1.3. Antipsychotic Agents
    • 8.1.4. Others

9. Prion Disease Treatment Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Homecare settings
    • 9.1.4. Others

10. Prion Disease Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Prion Disease Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Prion Disease Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Prion Disease Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Prion Disease Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Prion Disease Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Prion Disease Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. CureVac AG
    • 11.2.2. Prionics AG
    • 11.2.3. Neurotech Pharmaceuticals
    • 11.2.4. Prothena Biosciences
    • 11.2.5. Alnylam Pharmaceuticals
    • 11.2.6. IONIS Pharmaceuticals
    • 11.2.7. Biogen
    • 11.2.8. Eli Lilly and Company
    • 11.2.9. Amgen Inc.
    • 11.2.10. Genentech
    • 11.2.11. Wave Life Sciences
    • 11.2.12. Orphazyme A/S
    • 11.2.13. Sage Therapeutics
    • 11.2.14. Alector Inc.
    • 11.2.15. Tetra Discovery Partners

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us